Company: ABBV
Filing Date: 2025-11-04
Form Type: 10-Q
Source: 0001551152-25-000049
Chunk: 24

Company: AbbVie Inc.
Filing Date: 2025-11-04
Form: 10-Q
Item: Part I, Item 1
Chunk 24
---
idiaries Condensed Consolidated Statements of Comprehensive Income (unaudited) 

Three months endedSeptember 30,Nine months endedSeptember 30,(in millions)2025202420252024Net earnings$188 $1,564 $2,418 $4,309 Foreign currency translation adjustments, net of tax expense (benefit) of $(2) for the three months and $48 for the nine months ended September 30, 2025 and $25 for the three months and $1 for the nine months ended September 30, 2024(49)574 1,489 21 Net investment hedging activities, net of tax expense (benefit) of $4 for the three months and $(265) for the nine months ended September 30, 2025 and $(91) for the three months and $(11) for the nine months ended September 30, 202411 (330)(970)(39)Pension and post-employment benefits, net of tax expense (benefit) of $1 for the three months and $1 for the nine months ended September 30, 2025 and $(1) for the three months and $3 for the nine months ended September 30, 20243 (3)5 15 Cash flow hedging activities, net of tax expense (benefit) of $1 for the three months and $(19) for the nine months ended September 30, 2025 and $(8) for the three months and $(3) for the nine months ended September 30, 2024(1)(62)(173)(26)Other comprehensive income (loss)(36)179 351 (29)Comprehensive income152 1,743 2,769 4,280 Comprehensive income attributable to noncontrolling interest2 3 8 9 Comprehensive income attributable to AbbVie Inc.$150 $1,740 $2,761 $4,271 

The accompanying notes are an integral part of these condensed consolidated financial statements.

2025 Form 10-Q | 2

AbbVie Inc. and Subsidiaries Condensed Consolidated Balance Sheets 

(in millions, except share data)September 30,2025December 31, 2024(unaudited)AssetsCurrent assetsCash and equivalents$5,629 $5,524 Short-term investments42 31 Accounts receivable,